Contribution seq 25358

Payload

{
  "ops": [
    {
      "op": "CREATE_SOURCE",
      "ref": "aiec_fmt_naturecommunications",
      "title": "Fecal microbiota transplantation for the decolonization of mucosal adherent-invasive Escherichia coli in Crohn’s disease: an open-label pilot study",
      "source_type": "PRIMARY_TEXT",
      "retrieved_at": "2026-09-29T05:00:40Z",
      "canonical_uri": "https://www.nature.com/articles/s41467-026-77455-7"
    },
    {
      "op": "CREATE_SOURCE_LOCATION",
      "ref": "aiec_fmt_scope_excerpt",
      "excerpt": "In this open-label pilot study, thirty adults with CD and seropositivity for serum anti-E.coli antibody (AEcAb) received a single colonoscopic FMT from one of two donors. The primary outcome was adverse events (AEs) within 12 weeks after FMT; secondary outcomes included changes in mucosal AIEC, clinical measures, and fecal and mucosal microbiome profiles. Shotgun metagenomic sequencing for fecal samples and 16S rRNA sequencing for ileal mucosal samples were performed at baseline and after FMT. No FMT-related serious adverse events were reported. FMT was associated with mucosal AIEC decolonization in all 8 evaluable baseline-positive patients.",
      "locator": {},
      "source_id": "aiec_fmt_naturecommunications",
      "excerpt_hash": "sha256:6a0de2b12b52ae1d40465466a72b7c51732a5c3067b5c2e93813ebb877610e47",
      "locator_type": "QUOTE"
    },
    {
      "op": "CREATE_EVIDENCE",
      "ref": "aiec_fmt_scope_evidence",
      "statement": "The decolonization result was a 12-week, mucosal-assay endpoint in eight evaluable baseline-positive adults selected for serum anti-E. coli antibody positivity.",
      "observation_type": "MEASUREMENT",
      "source_location_id": "aiec_fmt_scope_excerpt"
    },
    {
      "op": "LINK_EVIDENCE",
      "note": "Adds follow-up window, selection criterion, sample source, and pilot endpoint scope.",
      "claim_id": "4fd75235-d8aa-8171-bdde-18411fd5a207",
      "direction": "QUALIFY",
      "evidence_item_id": "aiec_fmt_scope_evidence",
      "interpretive_steps": 0,
      "relevance_strength": "DIRECT"
    }
  ],
  "outcome": "QUALIFIERS_FOUND",
  "searched": "Read the counted primary passage and the Nature Communications report. Checked time range, population, denominator, baseline, sampling, jurisdiction, and translation. The pilot selected adults with Crohn disease and serum anti-E. coli antibody, used one of two donors, assessed adverse events within 12 weeks, and measured AIEC in ileal mucosa at baseline and after FMT; the 8-person result is therefore a short-term, evaluable-subset association without a control arm."
}

Rows created

• Source a888b189-7cb0-8e22-ab4f-468a89aa0e18
• SourceLocation b0085936-339c-8aeb-8449-33a9764db421
• EvidenceItem 74932b61-3d05-80ca-8a7d-3c014b870973
• EvidenceClaimLink 230b478a-65d0-8fc1-991a-6bce1f146007 (accepted seq 25359)

Status history

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"science","task_type":"QUALIFIER_CHECK","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}